Okubo Kazuki, Horiguchi Akio, Ito Keiichi, Asano Tomohiko
Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Urol Case Rep. 2018 Jun 6;20:22-24. doi: 10.1016/j.eucr.2018.05.018. eCollection 2018 Sep.
Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction immediately after pazopanib administration accompanied by severe liver dysfunction. His liver function was restored conservatively by giving him hepatoprotectors and having him stop taking pazopanib. The recurrent tumor disappeared but by 4 months later had regrown.
帕唑帕尼是一种口服生物可利用的酪氨酸激酶抑制剂抗癌药物，在全球范围内被批准用于治疗转移性肾细胞癌和晚期软组织肉瘤。在此，我们报告一例复发性腹膜后软组织肉瘤患者的病例，该患者在服用帕唑帕尼后肿瘤立即大幅缩小，但同时伴有严重肝功能障碍。通过给予其肝脏保护剂并停用帕唑帕尼，其肝功能得到保守治疗恢复。复发性肿瘤消失，但4个月后又重新生长。
